Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.66 |
| ▸ | PPARA | Q07869 | 13/20 | 0.66 |
| ▸ | PPARD | Q03181 | 10/20 | 0.66 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094056 | 0.92 | PPARD (0.55) | PPARGPPARAPPARDS1PR3S1PR5 | |
| SCHEMBL5096381 | 0.90 | PPARG (0.54) | PPARGPPARAPPARDS1PR3S1PR5 | |
| SCHEMBL5093890 | 0.90 | PPARG (0.57) | PPARGPPARAPPARDS1PR3S1PR5 | |
| SCHEMBL5090371 | 0.88 | PPARG (0.55) | PPARGPPARAPPARDS1PR3S1PR5 | |
| SCHEMBL5102363 | 0.84 | PPARG (0.55) | PPARGPPARAPPARDS1PR3S1PR5 | |
| SCHEMBL5102189 | 0.81 | PPARG (0.60) | PPARGPPARAPPARDFFAR4 | |
| SCHEMBL5102471 | 0.79 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5095981 | 0.79 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5102285 | 0.79 | PPARG (0.88) | PPARGPPARAPPARD | |
| SCHEMBL5090306 | 0.78 | PPARG (0.50) | PPARGPPARAPPARDS1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.